MediLink has developed ADC-related technologies with independent intellectual property rights, covering several tumor areas with the highest incidence and mortality rates.
The following table shows the latest progress of the clinical stage pipelines of MediLink.
Project
Target
Indications
Platform
Collaboration
Discovery
Pre -Clinical
IND
Phase 1
Phase 2
Phase 3
BLA
B7H3
Solid Tumor
YL202
HER3
Solid Tumor
BioNTech
YL205
NaPi2b
Solid Tumor
YL217
CDH17
Solid Tumor
YL242
VEGF
Solid Tumor
YL211
C-MET
Solid Tumor
Roche
YL212
DLL3
Solid Tumor
Zai Lab
YL215
MSLN
Solid Tumor
Harbour
YL221
EGFR
Solid Tumor
Henlius
YL222
PDL1
Solid Tumor
Henlius
